Skip to content
Back to meeting Original
EGFR Positive Lung Cancer UK· @EgfrUk · X·· 1 day agoScore70

SAFFRON

Body

What happens when osimertinib stops working? A major concern for our EGFR+ #lungcancer community.

SAFFRON Phase III: 17.8 vs 12.9 months median survival with osimertinib + savolitinib vs chemotherapy in MET-altered disease.

Promising results #ESMO2026. Now, what about UK access?

https://www.nejm.org/doi/full/10.1056/NEJMoa2611335 #LCSM

9 views · 1 like · 0 reposts · 0 replies

Source: EGFR Positive Lung Cancer UK · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website’s feedback page.